Wockhardt share price
High risk
You have to be logged in to add this to Watchlist.- ₹1,320.30(-1.50%)May 22, 2025 15:29:45 PM IST
- NSE
- BSE
- Vol : 344.34K (NSE + BSE)Last 20 day avg : 460.04 K
Wockhardt is trading -1.50% lower at Rs 1,320.30 as compared to its last closing price. Wockhardt has been trading in the price range of 1,345.00 & 1,298.45. Wockhardt has given -6.82% in this year & 2.87% in the last 5 days. The company posted a net profit of 13.00 Crores in its last quarter.Listed peers of Wockhardt include Gland Pharma (-1.92%), Syngene International (-0.40%), Wockhardt (-1.50%).The Mutual Fund holding in Wockhardt was at 7.56% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Wockhardt was at 6.81% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Key Metrics
Updated on May 23, 2025, 02:53 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.03The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.88Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.70The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Wockhardt News
Wockhardt Financials
Financials
View allFinancials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
- Income
- Balance Sheet
- Cash Flow
Loading...
Units in the chart are in crores
Insights
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 2.85% from Rs 721.00 crore to Rs 701.00 crore, year-on-year
- Company has registered a profit of 13.00 cr vs a loss of 83.00 cr in the same quarter last year.
The debt to equity of the company is higher than the industry median- Earnings are insufficient to cover the interest expenses on outstanding debt
Wockhardt Technical Analysis
Pivot Level - classic
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
- R1
- 1,396.85
- R2
- 1,497.00
- R3
- 1,600.00
Pivot1,293.85
- S1
- 1,193.70
- S2
- 1,090.70
- S3
- 990.55
Short Term
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Considers price movement over the last 6 months
Not Available
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Trends unavailable at the moment.
Wockhardt Peers
Return Comparison
Peers Comparison
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Gland Pharma | Neutral | 1,542.35 | -1.92 | 25,411.21 | 37.06 | 2.83 | 1.15 | 1.17 |
| Syngene International | Bearish | 636.45 | -0.40 | 25,619.46 | 54.45 | 5.43 | 0.20 | 8.65 |
| Wockhardt | Neutral | 1,320.30 | -1.50 | 21,485.76 | - | 6.13 | - | 31.59 |
| Eris Lifesciences | Bullish | 1,519.50 | 0.97 | 20,666.53 | 58.35 | 7.19 | 0.49 | 62.42 |
| Alembic Pharmaceuticals | Moderately Bullish | 962.70 | 0.09 | 18,939.87 | 33.01 | 3.64 | 1.14 | 0.90 |
Wockhardt Shareholding
View AllShareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
Shareholding pattern for Wockhardt is currently unavailable
Please check back later.
Shareholding Insights
- Pledged found - Promoter(s) have pledged 18.24% of shares.
- Promoter(s) have increased pledged shares to 16.98% from 18.24% earlier.
- Promoter(s) holding is moderate at 49.09%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has increased by 0.28 percentage points from previous quarter
- Mutual Funds holding has increased by 0.43 percentage points from previous quarter
Mutual Fund Ownership
View allWockhardt Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-07 | Quarterly Results |
| 2024-11-13 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
| 2024-05-28 | Audited Results |
| 2024-03-26 | Others |
About the company Wockhardt
- IndustryBiotechnology & Drugs
- ISININE049B01025
- BSE Code532300
- NSE CodeWOCKPHARMA
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL TABLET, METHYCOBAL INJ, METHYCOBAL D, HAPID, PROXYFEN NANO GEL, LIVATIRA TABLET, LIVATIRA INJ, GABAWOK NT 100, GABAWOK NT 400, ETOBRIX 90, ETOBRIX TH4, ETOBRIX P, GLARZEN CARTRIDGE, GLARZEN DISPOPEN 2, ESOWOK D, TERITIDE, GLIMADAY, SITAWOK, GLARITUS, TRIMETADAY, MOPADAY, INOGLA, and ZINODAP. The Company has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
Wockhardt Share Price FAQs
Wockhardt is trading at 1320.30 as on Thu May 22 2025 09:59:45. This is -1.50% lower as compared to its previous closing price of 1340.40.
The market capitalization of Wockhardt is 21485.76 Cr as on Thu May 22 2025 09:59:45.
The 52 wk high for Wockhardt is 1678.60 whereas the 52 wk low is 489.20
Wockhardt can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 25.03
- Dividend Yield: 0.00%
- D/E ratio: -
Wockhardt reported a net profit of -463.00 Cr in 2024.
The Mutual Fund Shareholding was 7.56% at the end of 31 Mar 2025.
Quick Links